Dr. Hengrui Liu is a Research Associate at the Early Cancer Institute, Department of Oncology, University of Cambridge School of Clinical Medicine, and a Visiting Scientist at the Cancer Research UK (CRUK) Cambridge Institute. He also serves as Principal Investigator at Tianjin Yinuo Biomedical Co., Ltd., part-time Researcher at the Cancer Research Institute of Jinan University, and Science Project Mentor at Lumiere Education. Previously, he held the position of Principal Investigator at Shenzhen Biocomma Co., Ltd.
Dr. Hengrui Liu obtained his PhD in Biochemistry from the University of Cambridge, United Kingdom. Earlier, he completed a research internship at Stony Brook University, New York, USA, and served as a visiting researcher in the Department of Anesthesiology and Cancer Laboratory at Stony Brook Hospital.
He has received numerous awards and honors, including undergraduate scholarships, the Chinese National Exemption Recommendation for Outstanding Graduate Admission, the Graduate First-Class Scholarship, the Academic Progress Award from Stony Brook University, the First Prize for Poster Presentation at the Cambridge Ion Channel Forum, the Chinese Government Award for Outstanding Self-Financed Students Abroad, and the Charles Slater Fund from the University of Cambridge. In 2019, he was elected a member of the Cambridge Philosophical Society, and in 2025 was listed among the “Stanford/Elsevier Top 2% Scientists Worldwide.”
Dr. Hengrui Liu has published over 90 peer-reviewed papers as first or corresponding author in leading journals, with more than 3,600 citations, an h-index of 37, and an i10-index of 56. He has authored three professional textbooks, including Chinese Pharmacology, a national higher education textbook recognized by the National Health Commission of China, and holds five national patents, four of which have been commercialized.
